HomeScreenerSLDBProfile
D
38/100

Solid Biosciences

SLDBGene Therapy
📋
Analyst Summary
✓ VERIFIED2026-04-11

Solid Biosciences (SLDB) is the lead sponsor of 5 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 2 Phase 2[2], 4 Phase 1[3].

Trial NCT07160634[5] evaluates SGT-003 in Duchenne Muscular Dystrophy with a target enrollment of 80 participants.

SLDB has 1 Form 4 insider filing recorded at the SEC in the past 30 days[6].

Sources

  1. ClinicalTrials.gov (2026-04-11)
  2. ClinicalTrials.gov (2026-04-11)
  3. ClinicalTrials.gov (2026-04-11)
  4. ClinicalTrials.gov (2026-04-11)
  5. ClinicalTrials.gov · NCT07160634 (2026-03-03)
  6. SEC EDGAR · 0001707502 (2026-04-11)
🔬
Clinical Trials
5
NCT03368742Duchenne Muscular Dystrophy
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06138639Duchenne Muscular Dystrophy
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07148089Catecholaminergic Polymorphic Ventricular Tachycardia
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07160634Duchenne Muscular Dystrophy
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07180355Friedreich's Ataxia (FA)
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
1 filing
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Data Provenance
cik1 verified
clinical trial5 verified
insider buy1 verified
trial count4 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR